BERGUI, Mauro

BERGUI, Mauro  

NEUROSCIENZE "RITA LEVI MONTALCINI"  

Mostra records
Risultati 1 - 20 di 34 (tempo di esecuzione: 0.03 secondi).
Titolo Data di pubblicazione Autore(i) File
A 4-year multicenter follow-up of neutralizing anti-interferon antibodies in ms patients treated with high dose (375 mcg) interferon beta-1b 2006 A. TAVELLA; A. RICCI; P. BARBERO; A. PIPIERI; A. CUCCI; B. FERRERO; A. ROVERA; G. CONTESSA; M. BERGUI; E. VERSINO; M. CLERICO; L. DURELLI; FOR THE OPTIMS TRIAL STUDY GROUP
A comparison of fully automatic and semi-manual contouring software for quantitative magnetic resonance imaging of lesion load in multiple sclerosis 2005 E. Festa; P. Barbero; A. Pipieri; M. Bergui; A. Boghi; G. Bradac; L. Giordano; L. Durelli
CEREBELLUM INTRINSIC CONNECTIVITY IN EATING DISORDERS 2012 F. D’AGATA, P. CAROPPO, L. LAVAGNINO, M. CAGLIO, A. SPALATRO, C. SETTANTA, M. CORIASCO, F. FERRIO, M. BERGUI, F. AMIANTO, S. FASSINO, L. PINESSI, P. MORTARA
Correlation of anti-interferon beta neutralising antobodies with clinical response and mri activity in the INCOMIN (independent comparison of interferon) trial. 2003 P. BARBERO; E. VERDUN; M. CLERICO; A. PIPIERI; A. RICCI; M. BERGUI; E. VERSINO; G. ANTONELLI; M. ZAFFARONI; A. GHEZZI; E. MONTANARI; L. DURELLI; AND INCOMIN STUDY GROUP
Differences in primary motor cortex identification by BOLD fMRI in patients with AVMs and gliomas 2003 M. Bergui; M. Bregu; A. Boghi; G. B. Bradac
Different pathogenesis of thalidomide neuropathy in multiple myeloma. 2002 G. ISOARDO; D. COCITO; P. BARBERO; M. BERGUI; P. CIARAMITARO; A. BERTOLA; M. BOCCADORO; B. BERGAMASCO; L. DURELLI
Different pathogenesis of thalidomide neuropathy in multiple myeloma. 2002 G. ISOARDO; D. COCITO; P. BARBERO; M. BERGUI; P. CIARAMITARO; A. BERTOLA; M. BOCCADORO; B. BERGAMASCO; L. DURELLI
Diffusion Tensor and Voxel Based Morphometry study in patients with amyotrophic lateral sclerosis 2012 Paola Caroppo, Federico D’Agata, Maria Federica Ferrio, Mario Coriasco, Andrea Calvo, Adriano Chiò, Dorico Righi, Paolo Mortara, Gianni Boris Bradac, Mauro Bergui
Every-other-day interferon beta-1b compared with once weekly interferon beta 1-a in ms. further analysis of treatment effect on mri activity and neutralizing antibodies (nabs) in the INCOMIN trial 2004 P. BARBERO; M. BERGUI; A. RICCI; E. VERSINO; A. PIPIERI; E. VERDUN; M. CLERICO; L. GIORDANO; A. CUCCI; L. DURELLI; INCOMIN STUDY GROUP
Every-other-day interferon beta-1b compared with once-weekly interferon beta-1a in MS. Further analysis of treatment effect on MR1 activity and neutralising antibodies (NAbs) in the INCOMIN Trial 2004 P. Barbero; A. Ricci; M. Bergui; E. Verdun; E. Versino; E. Montanari; A. Ghezzi; M. Zaffaroni; L. Durelli
Focal gray matter decrease in the cerebral pain network of migraine patients 2006 Valfre' W; Rainero I; Bergui M; Bradac GB; Gentile S; Ferrero M; Rubino E; Vaula G; Pinessi L
High dose interferon beta-1b in aggressive Multiple Sclerosis. tolerability, clinical and mri results after one year of treatment 2006 A. PIPIERI; P. BARBERO; M. BERGUI; E. VERSINO; M. CLERICO; L. GIORDANO; L. DELFICO; G. CONTESSA; A.M. CUCCI; E. VERDUN; I. PESCI; L. MANNESCHI; E. CARTECHINI; E. PUCCI; G. GIULIANI; E. MONTANARI; L. DURELLI
High-dose interferon beta-1b (500 mcg every-other-day, subcutaneously) treatment in RR MS patients. Safety and MRI results of 1-year follow-up 2005 P. Barbero; A. Pipieri; E. Verdun; M. Bergui; M. Clerico; A. Ricci; L. Giordano; A. Rovera; E. Cartechini; G. Giuliani; E. Pucci; E. Montanari; L. Manneschi; L. Durelli
High-dose interferon-beta-1b (500 mcg every-other-day, subcutaneously) treatment in MS patients. Long-term evaluation and longitudinal comparison with preceding treatment with lower IFN beta dose 2004 P. Barbera; A. Pipieri; E. Verdun; M. Clerico; A. Ricci; M. A. Cucci; L. Giordano; E. Cartechini; G. Giuliani; E. Montanari; M. Bergui; L. Durelli
IFN beta-1b 500 mcg every-other-day, subcutaneously in MS patients. Tolerability, clinical and MRI results after one year of treatment 2005 M. Clerico; A. Pipaeri; P. Barbero; M. Bergui; F. Bruno; E. Verdun; L. Giordano; A. Ricci; E. Pucci; G. Giuliani; E. Cartechini; L. Manneschi; E. Montanari; E. Versino; A. Cucci; L. Durelli
IFN beta-1b in multiple sclerosis: comparing two different doses (the Optims Study). 2004 E. VERDUN; P. BARBERO; A. PIPIERI; A. RICCI; M. CLERICO; A. CUCCI; M. BERGUI; E. VERSINO; L. GIORDANO; M. ZAFFARONI; E. MONTANARI; G. GIULIANI; L. DURELLI; AND THE OPTIMS STUDY GROUP
Increasing dose of ifn beta 1b in ms patients: preliminary nab results from the optims study. 2003 VERDUN E; A. RICCI; P. BARBERO; M. CLERICO; A. PIPIERI; M. BERGUI; E. VERSINO; A. CUCCI; J.J. ZHONG; L. DURELLI; AND OPTIMS STUDY GROUP
Interferon beta-1b 500 mcg every-other-day in ms patients. Clinical and mri results 2005 P. BARBERO; A. PIPIERI; M. BERGUI; E. VERSINO; L. GIORDANO; M. CLERICO; A. RICCI; A. CUCCI; G. CONTESSA; M.L. GENESIA; E. PUCCI; E. CARTECHINI; L. MANNESCHI; I. PESCI; G; GIULIANI; E. MONTANARI; L. DURELLI
Interferon beta-1b 500 mcg every-other-day, subcutaneously in ms patients. Tolerability, clinical and mri results after one year of treatment 2005 M. CLERICO; A. PIPIERI; P. BARBERO; M. BERGUI; B. FERRERO; E. VERDUN; L. GIORDANO; A. RICCI; E. PUCCI; G. GIULIANI; E. CARTECHINI; L. MANNESCHI; E. MONTANARI; E. VERSINO; A. CUCCI; L. DURELLI
Interferon-beta-1b in multiple sclerosis: comparing two different doses (the OPTIMS Study) 2004 L. Durelli; E. Verdun; P. Barbero; A. Pipieri; A. Ricci; M. Clerico; M. A. Gucci; L. Giordano; M. Bergui; E. Versino